Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

NCT01175980 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Recurrent Oral Cavity Adenoid Cystic Carcinoma
Recurrent Salivary Gland Carcinoma
Salivary Gland Adenoid Cystic Carcinoma
Stage III Major Salivary Gland Cancer AJCC v7
Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Stage IVA Major Salivary Gland Cancer AJCC v7
Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Stage IVB Major Salivary Gland Cancer AJCC v7
Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Stage IVC Major Salivary Gland Cancer AJCC v7
Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Tongue Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Vorinostat

Sponsor

National Cancer Institute (NCI)